北京博星证券投资顾问有限公司（以下简称"本财务顾问""博星证券"） 接受收购人曹飞的委托，担任曹飞要约收购湖北济川药业股份有限公司（以下简 称"上市公司""公司"或"济川药业"）的财务顾问。博星证券作为本次要约 收购的收购方财务顾问，持续督导期为济川药业公告要约收购报告书之日起至要 约收购完成后的 12 个月止（即 2025 年 6 月 16 日至 2026 年 8 月 1 日）。2025 年 10 月 28 日，济川药业披露了《2025 年第三季度报告》。根据《中华人民共 和国证券法》和《上市公司收购管理办法》等法律法规和规则，本财务顾问就本 次持续督导期间内（即自 2025 年 7 月 1 日至 2025 年 9 月 30 日，以下简称"本 持续督导期"）规范运作、信息披露、履行公开承诺、落实后续计划等情况报告 如下： 一、关于本次要约收购情况概述 北京博星证券投资顾问有限公司 关于曹飞 要约收购湖北济川药业股份有限公司 之 2025 年第三季度持续督导意见 财务顾问 二〇二五年十一月 2025 年 6 月 11 日，曹龙祥与曹飞签署《股权转让协议》，曹龙祥将其持有 的江苏济川控股集团有限公司（以下简称" ...

重要内容提示： 委托现金管理受托方：平安证券股份有限公司（下称"平安证券"） 本次现金管理金额：人民币 4,920 万元 证券代码： 600566 证券简称： 济川药业 公告编号： 2025-091 湖北济川药业股份有限公司 关于全资子公司开立募集资金现金管理专用结算账户 并利用闲置募集资金进行现金管理的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 本次现金管理产品名称及本次现金管理期限：平安证券股份有限公司安 享 24 号浮动收益凭证：183 天 履行的审议程序：湖北济川药业股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日召开第十届董事会第十四次会议，于 2025 年 5 月 16 日召开 2024 年年度股东大会，审议通过了《关于全资子公司利用闲置募集资金和自有资金进 行现金管理的议案》，同意公司在不影响募投项目正常实施并保证募集资金安全 的前提下，使用额度不超过 5.8 亿元（含本数）的闲置募集资金进行现金管理， 投资对象为安全性高、流动性好、有保本约定、投资期限不超过 12 个月的投资 产 ...

Core Insights - The Chinese medicine market is experiencing rapid growth, driven by favorable policies and increasing market demand, as highlighted by the recent 12th World Traditional Chinese Medicine Conference held in Sydney, Australia [1][2]. Group 1: Market Performance - As of November 10, 2025, the Zhongzheng Traditional Chinese Medicine Index (930641) rose by 1.11%, with notable increases in stocks such as Zhongsheng Pharmaceutical (002317) up 3.69% and Kangyuan Pharmaceutical (600557) up 3.22% [1]. - The Traditional Chinese Medicine ETF (159647) increased by 0.88%, with the latest price reported at 1.03 yuan [1]. Group 2: Industry Growth Drivers - The conference attracted over 800 representatives from 24 countries, emphasizing the global interest in the dissemination and technological innovation of traditional Chinese medicine [1]. - Pacific Securities notes that the industry is supported by comprehensive measures across supply, payment, and demand sides, including registration, review, quality control, and cultural promotion [1]. Group 3: Key Constituents - As of October 31, 2025, the top ten weighted stocks in the Zhongzheng Traditional Chinese Medicine Index accounted for 54.92% of the index, including major players like Yunnan Baiyao (000538) and Tongrentang (600085) [2].

Core Viewpoint - Recent data indicates a significant rise in influenza activity in China, with a notable increase in patients visiting hospitals for treatment, prompting the need for early antiviral therapy and consideration of various factors in drug selection [1][2][3] Group 1: Influenza Activity - The latest report from the Chinese Center for Disease Control and Prevention shows a marked increase in influenza activity, particularly in southern provinces, with the percentage of influenza-like illness (ILI) cases reported at 4.6%, up from 4.1% the previous week [2] - Northern provinces reported an ILI percentage of 5.1%, significantly higher than the previous week's 3.7% and above levels from 2022, 2023, and 2024 [2] - A total of 347 influenza-like illness outbreaks were reported nationwide, with 245 cases identified as A(H3N2) [2] Group 2: Treatment and Drug Approval - The increase in influenza cases has led to a rise in hospital visits, particularly in pediatric departments, with doctors recommending early antiviral treatment within 48 hours of symptom onset [4] - Oseltamivir remains the preferred antiviral treatment, especially for children and immunocompromised patients, with over 120 approvals for related products from various companies [4][5] - The market for oseltamivir is dominated by Dongyangguang Pharmaceutical, holding over 70% market share in the past three years [4] Group 3: New Drug Developments - Several new RNA polymerase inhibitors have been approved in China, with the year 2025 being referred to as the "Year of Domestic Influenza New Drugs" [1][6] - Roche's Marbofloxacin has seen a significant increase in demand, with supply pressures leading to local production initiatives [6][7] - Other domestic companies, such as Qingfeng Pharmaceutical and Zhongsheng Pharmaceutical, have also launched new antiviral drugs, contributing to a broader range of treatment options for influenza [7][8] Group 4: Market Dynamics - The price of Marbofloxacin ranges from 195 to 234 yuan per pack, with no adjustments made by Roche despite increased demand [7] - Companies like Haizheng Pharmaceutical have reported a significant rise in demand for their antiviral products, with ongoing supply guarantees in place [8][9] - The market is seeing increased competition as more domestic firms enter the RNA polymerase inhibitor space, with several products currently in clinical trials or awaiting approval [9]

Core Viewpoint - The A-share market shows a slight decline with the Shanghai Composite Index closing at 3997.56 points, down 0.25%, while the total trading volume reached 20202.05 billion yuan, indicating a mixed performance among stocks breaking through the annual line [1] Group 1: Stock Performance - A total of 52 A-shares have surpassed the annual line today, with notable stocks including Luzhou Laojiao, Qiaoyuan Co., and Jiachuan Vision, which have deviation rates of 6.56%, 5.10%, and 4.86% respectively [1] - Stocks with smaller deviation rates that have just crossed the annual line include Lubnorth Chemical, Phoenix Optical, and Wuzhou Special Paper [1] Group 2: Individual Stock Data - Luzhou Laojiao (000912) saw a price increase of 9.93% with a turnover rate of 2.87%, closing at 4.87 yuan, resulting in a deviation rate of 6.56% [1] - Qiaoyuan Co. (301286) increased by 14.19% with a turnover rate of 9.67%, closing at 30.66 yuan, with a deviation rate of 5.10% [1] - Jiachuan Vision (300264) rose by 5.38% with a turnover rate of 10.65%, closing at 6.27 yuan, leading to a deviation rate of 4.86% [1]

Core Points - Jichuan Pharmaceutical experienced a 5.38% increase in stock price, reaching 26.65 CNY per share, with a trading volume of 298 million CNY and a turnover rate of 1.25%, resulting in a total market capitalization of 24.536 billion CNY [1] - The company, established on January 22, 1997, and listed on August 22, 2001, is primarily engaged in the research, production, and sales of pharmaceuticals, with revenue composition of 77.82% from traditional Chinese medicine, 19.27% from Western medicine, and 2.66% from other sources [1] Shareholder Analysis - Among the top circulating shareholders of Jichuan Pharmaceutical, a fund under Southern Fund holds a significant position. The Southern CSI 500 ETF (510500) reduced its holdings by 106,800 shares in the third quarter, now holding 5.375 million shares, which accounts for 0.59% of circulating shares [2] - The Southern CSI 500 ETF has a current scale of 140.098 billion CNY and has achieved a year-to-date return of 30.24%, ranking 1822 out of 4216 in its category, with a one-year return of 21.69%, ranking 2045 out of 3913 [2] - The fund manager, Luo Wenjie, has been in position for 12 years and 203 days, overseeing a total fund asset size of 170.445 billion CNY, with the best return during his tenure being 152.02% and the worst being -47.6% [2]

Core Viewpoint - Jichuan Pharmaceutical (600566) has completed the business registration change procedures and received a new business license from the Jingzhou Market Supervision Administration [1] Company Summary - The company has successfully updated its business registration, indicating a formal recognition of its operational status [1]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 湖北济川药业股份有限公司（以下简称"公司"）分别于 2025 年 8 月 22 日、2025 年 9 月 19 日召开第十届董事会第十六次会议和 2025 年第一次临时股 东大会，审议通过了《关于变更注册资本、取消监事会并修订<公司章程>的议案》, 具体内容详见公司在上海证券交易所网站（www.sse.com.cn）披露的《湖北济川 药业股份有限公司关于变更注册资本、取消监事会并修订<公司章程>的公告》。 近日，公司完成工商变更登记手续，领取了荆州市市场监督管理局换发的《营 业执照》，相关登记信息如下： 统一社会信用代码：91420000706963132M 证券代码： 600566 证券简称： 济川药业 公告编号： 2025-090 湖北济川药业股份有限公司 关于完成工商变更登记及换发营业执照的公告 成立日期：1997 年 1 月 22 日 法定代表人：曹龙祥 住所：湖北省荆州市沙市区园林路时尚豪庭 602 室 经营范围：药品研发；医药及其他领域投资管理；日化品销售；橡胶制品、 ...

Core Insights - The article highlights the top-performing stocks in the S&P China A-Share Dividend Opportunity Index, showcasing significant daily and year-to-date gains along with dividend yields [1]. Group 1: Stock Performance - Nanshan Aluminum (600219.SH) leads with a daily increase of 10.12% and a year-to-date gain of 21.05%, with a dividend yield of 3.71% [1]. - Chuanheng Co., Ltd. (002895.SZ) follows closely with a daily rise of 10.00% and an impressive year-to-date increase of 44.31%, offering a dividend yield of 4.14% [1]. - Shenhuo Co., Ltd. (000933.SZ) shows a daily increase of 7.38% and a year-to-date performance of 53.35%, with a dividend yield of 3.16% [1]. - Yuntianhua Co., Ltd. (600096.SH) has a daily gain of 7.04% and a year-to-date increase of 42.93%, with a dividend yield of 5.37% [1]. - Tianshan Aluminum (002532.SZ) reports a daily rise of 6.81% and a remarkable year-to-date gain of 79.73%, with a dividend yield of 2.87% [1]. Group 2: Additional Notable Stocks - Mercury Home Textiles (603365.SH) shows a daily increase of 6.43% and a year-to-date performance of 30.72%, with a dividend yield of 4.39% [1]. - Deyue Co., Ltd. (605117.SH) has a daily rise of 4.50% and a year-to-date increase of 37.54%, with a dividend yield of 3.35% [1]. - Yiyi Co., Ltd. (001206.SZ) reports a daily gain of 4.32% and an impressive year-to-date increase of 101.18%, with a dividend yield of 2.59% [1]. - China Foreign Trade (601598.SH) shows a daily increase of 3.32% and a year-to-date performance of 22.11%, with a dividend yield of 4.60% [1]. - COSCO Shipping Energy (600026.SH) has a daily rise of 2.56% and a year-to-date increase of 9.48%, with a dividend yield of 3.02% [1].

Core Insights - Jichuan Pharmaceutical (600566.SH) reported its Q3 2025 results, revealing that as of October 27, 2025, institutional investors held a total of 559 million shares, accounting for 60.68% of the company's total equity [1] - The proportion of shares held by institutional investors decreased by 0.76 percentage points compared to the previous quarter [1] - One public fund, the Southern CSI 500 ETF, reduced its holdings during this period, while 262 public funds did not disclose their holdings, including several notable funds focused on innovative drugs and traditional Chinese medicine [1] - One pension fund, the Basic Pension Insurance Fund 808 Combination, also saw a slight decrease in its holdings compared to the previous quarter [2] Institutional Holdings - A total of nine institutional investors disclosed their holdings in Jichuan Pharmaceutical, with significant players including Jiangsu Jichuan Holding Group and Agricultural Bank of China [1] - The overall institutional holding percentage stands at 60.68%, indicating a strong institutional interest despite a slight decline [1] Public Fund Activity - The Southern CSI 500 ETF was the only public fund to report a decrease in holdings, reflecting a minor reduction in its stake [1] - A total of 262 public funds did not disclose their holdings this quarter, indicating a potential shift in investment strategies or market conditions [1] Pension Fund Overview - The Basic Pension Insurance Fund 808 Combination was the only pension fund to report a decrease in holdings, suggesting a cautious approach among pension funds in the current market environment [2]